

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/526,697

Confirmation No. 9619

Applicant: Dudley et al.

Filed: May 5, 2005

TC/AU: 1644

Examiner: Michail A. Belyavskiy

Docket No.: 233876 (Client Reference No. E-275-2002/1-US-02)

Customer No.: 45733

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION UNDER 37 C.F.R. § 1.131

We, Mark E. Dudley, Steven A. Rosenberg, and John R. Wunderlich do hereby declare as follows:

1. We are the co-inventors of the pending claims in the above-referenced patent application.
2. We conceived of and reduced to practice the claimed invention in the United States before July 2, 2001, as evidenced by the following:
 - a. attached to this Declaration is a true and accurate copy of a report prepared by Mark E. Dudley. The report summarizes research performed involving the administration of non-myeloablative lymphodepleting chemotherapy followed by adoptive transfer of autologous T cells to melanoma patients. The autologous T-cells had been previously isolated and selected for highly avid recognition of an antigen of the melanoma by stimulation of the T-cells *in vitro* with the antigen of the melanoma. In patients A, B, E, and F, this *in vitro* stimulation of the T-cells was followed by one cycle of rapid

In re Appln. of Dudley et al.
Application No. 10/526,697

expansion using irradiated allogeneic feeder cells, OKT3 antibody, and
IL-2. IL-2 was subsequently administered to the patients.

3. The treatment dates of Patients A-F which have been deleted from the
report are prior to July 2, 2001.


4. Each of us hereby declares that all statements made herein of my own
knowledge are true, that all statements made on information and belief are believed to
be true, that these statements were made with the knowledge that willful false
statements and the like so made are punishable by fine or imprisonment, or both,
under Section 1001 of Title 18 of the United States Code, and that such willful false
statements may jeopardize the validity of the application or any patent issued thereon.

Date: _____

Date: 6/3/08

Date: _____

Mark E. Dudley, Ph.D.


Steven A. Rosenberg, M.D., Ph.D.

John R. Wunderlich, M.D.

ID#	Last	First	Patient Characteristics			Current Status			Patient Characteristics			Other			DOD	Dose Adj.
			Age	Sex	MRN	Date	Cells	Age	Res. (mg)	Next Dose	HLA	ASCT	HLA	ASCT	Res. (mg)	Next Dose
A	Patient	Patient	33.0	A	PR (29)	PR (29)	PR (29)	PR (29)	PR (29)	PR (29)	PR (29)	PR (29)	PR (29)	PR (29)	PR (29)	PR (29)
B	Patient	Patient	35.0	B	PR (30)	PR (30)	PR (30)	PR (30)	PR (30)	PR (30)	PR (30)	PR (30)	PR (30)	PR (30)	PR (30)	PR (30)
C	Patient	Patient	39.8	B	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
D	Patient	Patient	34.0	B	PR (2)	PR (2)	PR (2)	PR (2)	PR (2)	PR (2)	PR (2)	PR (2)	PR (2)	PR (2)	PR (2)	PR (2)
E	Patient	Patient	30.0	B	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M
F	Patient	Patient	56.5	A	PR (24)	PR (24)	PR (24)	PR (24)	PR (24)	PR (24)	PR (24)	PR (24)	PR (24)	PR (24)	PR (24)	PR (24)
G	Patient	Patient	122.6	M	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
H	Patient	Patient	94.5	G	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
I	Patient	Patient	93.7	M	PR (12)	PR (12)	PR (12)	PR (12)	PR (12)	PR (12)	PR (12)	PR (12)	PR (12)	PR (12)	PR (12)	PR (12)
J	Patient	Patient	159.0	M	PR (14)	PR (14)	PR (14)	PR (14)	PR (14)	PR (14)	PR (14)	PR (14)	PR (14)	PR (14)	PR (14)	PR (14)
K	Patient	Patient	130.0	M	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
L	Patient	Patient	137.0	M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M	NR-M
M	Patient	Patient	77.0	M	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

up stage CR